- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05458622
3TR (Taxonomy, Treatment, Targets and Remission) Systemic Lupus Erithematosus Study Protocol (3TR-SLE1)
The natural history of Systemic lupus erythematosus (SLE) is characterized by relapses or flares alternated with periods of remission. Flares are associated with accrual of organ damage independently of other risk factors, both contributing to a considerable morbidity. No useful biomarker is currently available to predict which patients with a quiescent disease are at risk of flare.
The 3TR project (funded by the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 831434, and supported by European Union's Horizon 2020 research and innovation programme and EFPIA) is a transdisciplinary consortium that primary aims at identifying biosignatures as predictors of response and non-response to therapy in seven different autoimmune, allergic and inflammatory diseases, including SLE. 3TR will perform a longitudinal multi-dimensional molecular analysis in patients with these diseases. A molecular profiling approach is a modern and innovative way to investigate and stratify heterogeneous diseases on the basis of their common biomolecular pathways. The main hypothesis of the 3TR project is that data obtained from multiomic analysis across the seven different diseases will identify shared biological pathways that better predict the response or non-response to therapy despite their differences in terms of clinical phenotypes and pathogenetic mechanisms. Therefore patients from multiple European centers participating in 3TR will be recruited for a longitudinal clinical follow-up and collections of several samples that will be used to perform multi-omic analysis.
Study Overview
Status
Conditions
Detailed Description
The study will be carried out in the framework of the IMI2 (innovative medicine initiative) and EFPIA (European Federation of Pharmaceutical Industries and Associations)-funded 3TR (Taxonomy, Treatment, Targets and Remission) project. The programme is supported by the European Union's Horizon 2020 research and innovation programme. 3TR is funded under the grant agreement No 831434 and it runs from 2019 to 2026.
3TR is a transdisciplinary consortium that aims to perform a longitudinal multi-dimensional molecular analysis in patients with autoimmune, allergic and inflammatory diseases. A molecular profiling approach is a modern and innovative way to investigate and stratify heterogeneous diseases on the basis of their common biomolecular pathways. The main hypothesis of the 3TR project is that data obtained from multiomic analysis across seven different diseases, including SLE, will identify shared biological pathways that better predict the response or non-response to therapy despite their differences in terms of clinical phenotypes and pathogenetic mechanisms. Patients from multiple European centers participating in 3TR will be recruited for a longitudinal clinical follow-up and collections of several samples that will be used to perform multi-omic analysis.
Several innovations are expected within the 3TR project to increase the knowledge of pathogenetic mechanisms underlying the clinical phenotypes in SLE, and to unravel, in the complexity of SLE biomolecular heterogeneity, the pathways of response or non-response to treatment, as well as, at an earlier stage, the processes that may lead to disease flare. These insights could ultimately allow the possibility to effectively practice prevention and counselling, to adopt measures of personalized treatment or to perform drug repurposing using the knowledge gained from the SLE studies and the studies on other diseases within the 3TR project.
Moreover, the impact of the COVID-19 viral pandemic will be implemented in our research. More specifically, we will investigate the impact of the presence of anti-SARS-CoV-2 antibodies of different isotypes (IgA, IgG, IgM) on the development of flare, as well as on the response or non-response to immunomodulatory therapy.
To implement the strategy, a two-step research has been designed, and comprises:
- The flare biomarker study (3TR SLE 1) is considered a "feeding" phase before the main part. Patients who meet the inclusion criteria for 3TR SLE 2 will be proposed to participate in the second study.
- The response biomarker study (3TR SLE 2), which is a prospective study (main part).
The present protocol relates to the flare biomarker study (3TR SLE 1).
Study Type
Enrollment (Anticipated)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Brest, France, 29609
- Recruiting
- 01- CHU Brest
-
Contact:
- Jean-Christophe Ianotto
- Email: jean-christophe.ianotto@chu-brest.fr
-
Principal Investigator:
- Sandrine Jousse
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age at the time of inclusion ≥ 18 years;
- Able to consent and agree to participate to the study.
- Diagnosis of SLE according to the EULAR/ACR criteria; BILAG C, D or E only;
- No restriction regarding current or previous therapies, except for hydroxychloroquine (HCQ) or chloroquine treatment which should be administered unless contraindicated or documented intolerance in the past.
Exclusion Criteria:
- Pregnancy and/or breastfeeding;
- Initiation or intensification of immunosuppressive therapy or a prednisone equivalent dose of > 10 mg/day within 30 days prior to baseline;
- Unable or unaware to participate to the study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: Stable or quiescent SLE
Patients included in this study will undergo one assessment at the time of recruitment and at the time of the end of study (time of a flare or at least 24 months after inclusion) The following information will be collected :
Biological samples which will be obtained twice, at baseline and at the time of the first flare documented over 24 months, or at month 24 if no flare has been documented:
|
- Total volume of blood (on each sampling occasion): 54,5mL.
- Urine: 100 mL which will be centrifuged.
The pellet will be frozen, and the urine supernatant will be aliquoted;
- Saliva: will be collect in special container for saliva microbiome and methylation;
- Stool: One sample for microbiome to be sent to the biobank, frozen at -80 °C
- Tissue samples for organ-specific manifestations:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Flare patient proportion according to the BILAG index at 24 months
Time Frame: 24 months
|
Number of patients developing a flare within 24 months of follow-up, defined as a new BILAG A or B in any clinical domain.
|
24 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Proportion of flare according to the SELENA-SLEDAI Flare Index
Time Frame: Flare or 24 months
|
Number of patients with a flare within 24 months, according to the SELENA-SLEDAI Flare Index (SFI).
Flare will be defined as a 4-point increase in SLEDAI-2 K.
|
Flare or 24 months
|
Anti-SARS-CoV-2 antibodies impact on risk of flare
Time Frame: Flare or 24 months
|
Number of patients with anti-SARS-CoV-2 antibodies of different isotypes (IgA, IgG, IgM) with and without a flare during 24 months of follow-up.
|
Flare or 24 months
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 29BRC21.0367 (3TR-SLE1)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Systemic Lupus Erythematosus (SLE)
-
University of Sao Paulo General HospitalFundação de Amparo à Pesquisa do Estado de São PauloCompletedSystemic Lupus Erythematosus (SLE) | Cutaneous Lupus | Juvenile SLEBrazil
-
AstraZenecaNot yet recruitingSystemic Lupus Erythematosus (SLE)
-
Hangzhou Sumgen Biotech Co., Ltd.RecruitingSystemic Lupus Erythematosus (SLE)China
-
Cartesian TherapeuticsRecruitingSystemic Lupus Erythematosus (SLE)United States
-
Oklahoma Medical Research FoundationYale University; Columbia University; NYU Langone Health; Piedmont Heart Institute...RecruitingSystemic Lupus Erythematosus (SLE)United States
-
Phramongkutklao College of Medicine and HospitalCompletedSystemic Lupus Erythematosus, SLEThailand
-
AmgenCompletedSystemic Lupus Erythematosus (SLE)United States, Korea, Republic of, Australia, Spain, Hungary, Bulgaria, Italy, Mexico, Germany, Japan, France, Greece, Czechia, Argentina, Portugal, Poland, Russian Federation, Hong Kong, Canada
-
MallinckrodtCompletedSystemic Lupus Erythematosus (SLE)United States
-
Hospices Civils de LyonCompletedSystemic Lupus Erythematosus (SLE)France
-
University Hospital, BrestRecruitingSystemic Lupus Erythematosus (SLE)France
Clinical Trials on Blood sample
-
Medical University of WarsawCompletedArthroplasty | Platelet Aggregation | Methylmethacrylate EmbolismPoland
-
Memorial Sloan Kettering Cancer CenterActive, not recruiting
-
Meir Medical CenterCompleted
-
University Hospital, ToursRecruitingRenal Transplant | ConversionFrance
-
Centre Hospitalier Universitaire de BesanconRecruitingInvasive Pulmonary AspergillosisFrance
-
Centre Hospitalier Universitaire DijonRecruitingAutoimmune Hemolytic AnemiaFrance
-
M.D. Anderson Cancer CenterTerminated
-
Duke UniversityUniversity of South Florida; Children's Hospital Los AngelesCompletedInfant Immunity Response and Immunoglobulin DiversityUnited States
-
University Hospital, ToulouseCompleted